Bridge to Life said it secured $110 million to expand commercialization of its Vitasmart hypothermic oxygenated perfusion (HOPE) system, which preserves donor organs prior to transplant. The company said the funding will build its commercial footprint for liver transplants in the U.S., develop a broader organ pipeline, and support a viability biomarker test. HOPE is being pitched as a potential new standard approach for increasing utilization of available organs amid high transplant waiting lists. The company’s strategy combines service expansion with diagnostic development to strengthen operational adoption. The capital also positions Bridge to Life to scale beyond liver applications if additional evidence supports broader use cases.